CN107941954A - A kind of Monitoring of drug resistance method of aspirin - Google Patents
A kind of Monitoring of drug resistance method of aspirin Download PDFInfo
- Publication number
- CN107941954A CN107941954A CN201711235562.4A CN201711235562A CN107941954A CN 107941954 A CN107941954 A CN 107941954A CN 201711235562 A CN201711235562 A CN 201711235562A CN 107941954 A CN107941954 A CN 107941954A
- Authority
- CN
- China
- Prior art keywords
- solution
- monitoring
- dehydrogenation
- thromboxane
- drug resistance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/62—Detectors specially adapted therefor
- G01N30/72—Mass spectrometers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/86—Signal analysis
- G01N30/8624—Detection of slopes or peaks; baseline correction
- G01N30/8631—Peaks
- G01N30/8634—Peak quality criteria
Landscapes
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Engineering & Computer Science (AREA)
- Quality & Reliability (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The invention discloses a kind of Monitoring of drug resistance method of aspirin, this method is realized by detecting 11 dehydrogenation thromboxane B2 contents in urine, is specially：Urine specimen is detected using liquid chromatography mass spectrometric method, brings 11 dehydrogenation thromboxane B2 concentration and creatine concentration that standard curve respectively obtains urine specimen into.The detection method high sensitivity of the present invention, test limit is low, and detection method step is simple, and quick and precisely, sample of the present invention only needs 30min from data are received out, substantially reduces the detection time of sample.
Description
Technical field
The present invention relates to a kind of detection method of interior metabolism product, more particularly to a kind of Monitoring of drug resistance of aspirin
Method.
Background technology
Aspirin is widely used in the primary and secondary prevention of cardiovascular and cerebrovascular disease as antiplatelet drug, can obviously reduce
All kinds of Embolism and thrombosis events, although but still having the aspirin of the long-term use of routine dose of some patientss（75-325mg）
Its platelet aggregation ability is thrown away not to be suppressed very well, is known as biochemical aspirin resistance, and thromboembolism thing still occurs for some patients
Part, is known as Clinical Aspirin Resistance or aspirin for treatment failure.As increasing for antiplatelet drug species exists with medicine
The inhomogeneity of biological action with patient, reaction of the detection individual to Antiplatelet therapy be significantly, can be with
The medication type and being optimal of dosage of individual are adjusted accordingly, to control and reduce the risk that thrombus and bleeding occurs.
Thromboxane A2（TXA2）It is that a kind of of arachidonic acid metabolic generation in blood platelet has strong biological activity
Material, is to be currently known one of most strong vaso-excitor material and most strong platelet aggregating agent, with the hematoblastic close phase of activation
Close, play an important role in the pathophysiological process of thrombus and thrombotic diseases.Due to its in vivo half-life period it is very short（About
30s）, therefore generally learn the generation water of TXA2 indirectly by detecting the concentration of its stabilization metabolite TXB2 in blood plasma in the past
It is flat, so as to understand the degree of internal platelet activation.But because of blood platelet Activated in Vitro during blood sampling sampling and experimental implementation
TXB2 can be produced, this just have impact on the accuracy of experimental result so that this index cannot really blood be small in antimer by TXB2
The level of plate activation.
In recent years, it has been found that the 11 dehydrogenation thromboxane B2 of Major Enzymes metabolite of TXBZ（11- DH-TXB2）Not in vitro
Generation, the dehydrogenase that catalysis TXB2 is changed into 11-DH-TXB2 is primarily present in liver, lung, kidney, therefore 11- DH-TXB2's is external dense
The influence from blood platelet Activated in Vitro is spent, and half-life period is also longer（About 46min）, therefore be platelet activation in antimer
One new strong specific sensitive indicator.Since contents of the 11-DH-TXB2 in urine is with amount of drinking water and the difference of sample time
Change greatly, existing frequently-used pg 11-DH-TXB2/mg creatinines standardize urine concentration.
The main method of measure 11-DH-TXB2 contents is RNA isolation kit now, this method complex steps, from sample treatment
Several hours are at least needed to data are obtained, according to the report of document, different experiments room data measured otherness is larger, data difference
It is different can be to two orders of magnitude even three orders of magnitude.Therefore kit is higher to requirements such as operating personnel, laboratory conditions, needs
The equipment such as biology personnel that will be professional and microplate reader.
The content of the invention
To make up the deficiencies in the prior art, the present invention provide it is a kind of it is quick, accurate, can truly reflect platelet activation degree
Aspirin Monitoring of drug resistance method, the purpose is to the medication guide of aspirin is provided for patient.
The present invention is achieved through the following technical solutions：
A kind of Monitoring of drug resistance method of aspirin, it is characterized in that：This method is by detecting 11 dehydrogenation blood in urine
Bolt alkane B2 contents are realized, are specially：Urine specimen is detected using liquid chromatography mass spectrometric method, standard curve is brought into and respectively obtains urine specimen
11 dehydrogenation thromboxane B2 concentration and creatine concentration.
Specifically, a kind of Monitoring of drug resistance method of aspirin of the present invention, comprises the following steps：
（1）The preparation of calibration curve solution
11 dehydrogenation thromboxane B2 solution are diluted step by step, dilution range 10pg/ml-25ng/ml, it is de- at different levels 11 after dilution
Internal standard solution is added in hydrogen thromboxane B2 solution, is uniformly mixed to obtain 11 dehydrogenation thromboxane B2 calibration curve solutions；By creatinine solution by
Level dilution, dilution range 1mg/dL-300mg/dL, internal standard solution is added into the creatinine solution at different levels after dilution, is uniformly mixed
Obtain creatinine calibration curve solution；
（2）The preparation of urine specimen to be measured
Internal standard solution will be added after human urine sample process, be uniformly mixed；
（3）The drafting of standard curve
By step（1）The 11 dehydrogenation thromboxane B2 calibration curve solutions and creatinine calibration curve solution obtained carry out liquid chromatography mass spectrometric inspection
Survey, linear regression analysis, respectively obtains 11 dehydrogenation thromboxane B2 solution standard curves and creatinine solution standard curve；
（4）Urine specimen detection to be measured
The urine specimen to be measured that step 2 is obtained carries out liquid chromatography mass spectrometric detection, brings into the standard curve that step 3 obtains, respectively
The 11 dehydrogenation thromboxane B2 concentration and creatine concentration of urine specimen are obtained, according to 11 dehydrogenation thromboxane B2 values（pg/ml）/ creatinine value
（mg/dL）× 100 calculate to obtain report value.
Further, the Monitoring of drug resistance method of a kind of aspirin of the invention, the internal standard solution are 11 dehydrogenation thrombus
The deuterated things of alkane B2（11- DH-TXB2-d4）Solution.
Further, the Monitoring of drug resistance method of a kind of aspirin of the invention, the processing of the urine specimen to be measured
Process is：Take human urine sample to add protein precipitant centrifugation, take supernatant to cross miillpore filter.
Further, the miillpore filter aperture is 0.22um.
Further, the Monitoring of drug resistance method of a kind of aspirin of the invention, step（3）In with 11 dehydrogenation thromboxanes
The deuterated things of B2（11- DH-TXB2-d4）As inner mark solution, using peak area as ordinate, carried out by abscissa of sample concentration
Linear regression analysis.
Further, the Monitoring of drug resistance method of a kind of aspirin of the invention, the liquid chromatography mass spectrometric method detection 11 are de-
Ion pair used in hydrogen thromboxane B2 solution is 381.2/265.2,381.2/260.0,381.2/144.2,369.3/247.9,
369.3/301.1,369.3/309.3；Ion pair used in the liquid chromatography mass spectrometric method detection creatinine solution is 114.3/99.0,
114.3/72.3,114.3/86.3.
The beneficial effects of the invention are as follows：
（1）The detection method high sensitivity of the present invention, test limit is low, and lower limit of quantitation can arrive 10pg/ml.
（2）The detection method range of linearity of the present invention is wide, and standard curve concentration range 10pg/ml-25ng/ml, can meet
The content range of normal person and cardiovascular related diseases 11 dehydrogenation thromboxane B2s in patient body.
（3）The detection method step of the present invention is simple, and quick and precisely, sample of the present invention is only needed from receiving out data
30min, substantially reduces the detection time of sample.
（4）The present invention uses liquid chromatography mass spectrometric method, method tolerance and favorable reproducibility.
Embodiment
The present invention will be further described in detail with reference to the specific embodiments, to help those skilled in the art
Inventive concept, technical solution to the present invention have more complete, accurate and deep understanding, and protection scope of the present invention is included but not
It is limited to following embodiments, any details to technical scheme on the premise of without departing from spirit and scope
Each fallen within the modification that form is made in protection scope of the present invention.
1. instrument and medicine
High performance liquid chromatograph：Shimadzu Nexera XR, pump：LC-20AD XR, autosampler：SIL -20AC XR, column temperature
Case：CTO-20A.Mass spectrograph：AB SCIEX API 4000, centrifuge：Thermo SORVALL ST 8R.
11- DH-TXB2 and 11- DH-TXB2-d4Purchased from Cayman ChemicalsCo, creatinine is purchased from middle inspection institute,
Acetonitrile, methanol are chromatographically pure, and water is two level purified water.
2. chromatographic test strip part
Chromatographic column：WATERS C18 2.5μm （2.1×75mm）Chromatographic column, mobile phase A are mutually methanol：2.5mmol/L ammonium acetate
=3：97, Mobile phase B is mutually methanol：Acetonitrile=3：97, flow velocity 0.2-0.3ml/min, 40 DEG C of column temperature, sampling volume 5ul.
3. the preparation of storing solution
（1）The preparation of 11- DH-TXB2 storing solutions：11 dehydrogenation thromboxane B2 solution of purchase are diluted to 100ng/ml, are marked
For Stock 1.
（2）11- DH-TXB2-d4The preparation of storing solution：By the 11- DH-TXB2-d of purchase4Solution is diluted to 10ng/ml,
Labeled as Stock 2.
（3）The preparation of creatinine storing solution：Creatinine solid 10mg is weighed, is added in 10ml volumetric flasks, adds purified water constant volume,
Labeled as Stock 3.
4. the preparation of calibration curve solution
（1）It is prepared by 11- DH-TXB2 calibration curve solutions：By storing solution stock1 dilutions（Purified water）It is diluted to step by step
25ng/ml, 5ng/ml, 1ng/ml, 200pg/ml, 50pg/ml, 10pg/ml.
Above-mentioned each strength solution 190ul is taken respectively, adds the storing solution Stock 2 of 10ul, is uniformly mixed, is obtained 11 dehydrogenation blood
Bolt alkane B2 calibration curve solutions.
（2）The preparation of creatinine calibration curve solution：By storing solution stock3 dilutions（Purified water）It is diluted to step by step
300mg/d, 100mg/dL, 50mg/dL, 20mg/dL, 5mg/dL, 1mg/dL.
Above-mentioned each strength solution 190ul is taken respectively, adds the storing solution Stock 2 of 10ul, is uniformly mixed, is obtained creatinine standard
Curve solution.
5. the preparation of urine specimen to be measured
Human urine sample 1ml is taken, protein precipitant 2ml, 1000 × g/min centrifugation 15min is added, takes supernatant to cross 0.22um
Miillpore filter.Take 190ul filtrates to add 10ul storing solution stock2, be uniformly mixed.
6 linear analysis
The 11 dehydrogenation thromboxane B2 calibration curve solutions and creatinine calibration curve solution for taking step 4 to obtain respectively, carry out liquid phase matter
Spectrum detection, is used in conjunction using liquid chromatograph-mass spectrometer and is detected, the chromatographic test strip part of 11 dehydrogenation thromboxane B2s is step 2 institute
State condition, the ion pair that mass spectrograph uses for 381.2/265.2,381.2/260.0,381.2/144.2,369.3/247.9,
369.3/301.1,369.3/309.3；The chromatographic test strip part of creatinine is condition described in step 2, mass spectrograph detection use from
Son is to for 114.3/99.0,114.3/72.3,114.3/86.3；Linear regression analysis：With 11- DH-TXB2-d4As internal standard
Solution, using peak area as ordinate, carries out linear regression analysis by abscissa of sample concentration, obtains 11 dehydrogenation thromboxane B2s
Standard curve and creatinine standard curve；Wherein, 11 dehydrogenation thromboxane B2 regression curve R2=0.9993, no weight；Creatinine returns
Curve R2=0.9989, no weight.
7. urine specimen detection to be measured
By 10 parts of human urine samples, liquid chromatography mass spectrometric detection is carried out, is used in conjunction and is detected using liquid chromatograph-mass spectrometer, brought into
The standard curve of step 6 respectively obtain urine specimen 11 dehydrogenation thromboxane B2 concentration and creatine concentration it is as shown in the table：
。
Claims (7)
1. a kind of Monitoring of drug resistance method of aspirin, it is characterised in that：This method is by detecting 11 dehydrogenation thrombus in urine
Alkane B2 contents are realized, are specially：Urine specimen is detected using liquid chromatography mass spectrometric method, standard curve is brought into and respectively obtains urine specimen
11 dehydrogenation thromboxane B2 concentration and creatine concentration.
A kind of 2. Monitoring of drug resistance method of aspirin according to claim 1, it is characterised in that：Including following step
Suddenly：
（1）The preparation of calibration curve solution
11 dehydrogenation thromboxane B2 solution are diluted step by step, dilution range 10pg/ml-25ng/ml, it is de- at different levels 11 after dilution
Internal standard solution is added in hydrogen thromboxane B2 solution, is uniformly mixed to obtain 11 dehydrogenation thromboxane B2 calibration curve solutions；By creatinine solution by
Level dilution, dilution range 1mg/dL-300mg/dL, internal standard solution is added into the creatinine solution at different levels after dilution, is uniformly mixed
Obtain creatinine calibration curve solution；
（2）The preparation of urine specimen to be measured
Internal standard solution will be added after human urine sample process, be uniformly mixed；
（3）The drafting of standard curve
By step（1）The 11 dehydrogenation thromboxane B2 calibration curve solutions and creatinine calibration curve solution obtained carry out liquid chromatography mass spectrometric inspection
Survey, linear regression analysis, respectively obtains 11 dehydrogenation thromboxane B2 solution standard curves and creatinine solution standard curve；
（4）Urine specimen detection to be measured
The urine specimen to be measured that step 2 is obtained carries out liquid chromatography mass spectrometric detection, brings into the standard curve that step 3 obtains, respectively
The 11 dehydrogenation thromboxane B2 concentration and creatine concentration of urine specimen are obtained, according to 11 dehydrogenation thromboxane B2 values（pg/ml）/ creatinine value
（mg/dL）× 100 calculate to obtain report value.
A kind of 3. Monitoring of drug resistance method of aspirin according to claim 2, it is characterised in that：The internal standard solution is
The deuterated thing solution of 11 dehydrogenation thromboxane B2s.
A kind of 4. Monitoring of drug resistance method of aspirin according to Claims 2 or 3, it is characterised in that：It is described to be measured
The processing procedure of urine specimen is：Take human urine sample to add protein precipitant centrifugation, take supernatant to cross miillpore filter.
A kind of 5. Monitoring of drug resistance method of aspirin according to Claims 2 or 3, it is characterised in that：Step（3）In
It is abscissa into line using sample concentration using peak area as ordinate using the 11 deuterated things of dehydrogenation thromboxane B2 as inner mark solution
Property regression analysis.
A kind of 6. Monitoring of drug resistance method of aspirin according to claim 4, it is characterised in that：The miillpore filter
Aperture is 0.22um.
A kind of 7. Monitoring of drug resistance method of aspirin according to Claims 2 or 3, it is characterised in that：The liquid phase
Mass spectrography detect 11 dehydrogenation thromboxane B2 solution used in ion pair be 381.2/265.2,381.2/260,381.2/144.2,
369.3/247.9,369.3/301.1,369.3/309.3；Ion pair used in liquid chromatography mass spectrometric method detection creatinine solution is
114.3/99,114.3/72.3,114.3/86.3.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711235562.4A CN107941954A (en) | 2017-11-30 | 2017-11-30 | A kind of Monitoring of drug resistance method of aspirin |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711235562.4A CN107941954A (en) | 2017-11-30 | 2017-11-30 | A kind of Monitoring of drug resistance method of aspirin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107941954A true CN107941954A (en) | 2018-04-20 |
Family
ID=61947940
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711235562.4A Pending CN107941954A (en) | 2017-11-30 | 2017-11-30 | A kind of Monitoring of drug resistance method of aspirin |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107941954A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112424604A (en) * | 2018-06-25 | 2021-02-26 | 瓦斯库技术公司 | Method and kit for detecting 11-dehydro-thromboxane B2 |
| CN115656400A (en) * | 2022-11-09 | 2023-01-31 | 大连博源医学科技有限公司 | Method for detecting 11-dehydrothromboxane B in urine 2 Liquid chromatography-tandem mass spectrometry method and kit |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070202556A1 (en) * | 2005-12-09 | 2007-08-30 | Corgenix Medical Corporation | Methods and kits for detection of thromboxane a2 metabolites |
| CN102680599A (en) * | 2012-05-11 | 2012-09-19 | 上海特敏生物医药科技有限公司 | Urinary sarcosine and creatinine assay kit |
| CN102980968A (en) * | 2012-12-29 | 2013-03-20 | 国家烟草质量监督检验中心 | Liquid chromatogram tandem mass spectrum measuring method for creatinine in urine |
| CN103941007A (en) * | 2014-03-28 | 2014-07-23 | 瑞莱生物科技（江苏）有限公司 | Immunofluorescence test strip for fast and quantitatively detecting curative effect of aspirin and preparation method of immunofluorescence test strip |
-
2017
- 2017-11-30 CN CN201711235562.4A patent/CN107941954A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070202556A1 (en) * | 2005-12-09 | 2007-08-30 | Corgenix Medical Corporation | Methods and kits for detection of thromboxane a2 metabolites |
| CN102680599A (en) * | 2012-05-11 | 2012-09-19 | 上海特敏生物医药科技有限公司 | Urinary sarcosine and creatinine assay kit |
| CN102980968A (en) * | 2012-12-29 | 2013-03-20 | 国家烟草质量监督检验中心 | Liquid chromatogram tandem mass spectrum measuring method for creatinine in urine |
| CN103941007A (en) * | 2014-03-28 | 2014-07-23 | 瑞莱生物科技（江苏）有限公司 | Immunofluorescence test strip for fast and quantitatively detecting curative effect of aspirin and preparation method of immunofluorescence test strip |
Non-Patent Citations (2)
| Title |
|---|
| SUBHASHINI YATURU ET AL.: "Aspirin resistance in young men with Type 2 diabetes", 《JOURNAL OF DIABETES MELLITUS》 * |
| VIVIANA CAVALCA ET AL.: "Simultaneous quantification of 8-iso-prostaglandin-F2a and 11-dehydro thromboxane B2 in human urine by liquid chromatography-tandem mass spectrometry", 《ANALYTICAL BIOCHEMISTRY》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112424604A (en) * | 2018-06-25 | 2021-02-26 | 瓦斯库技术公司 | Method and kit for detecting 11-dehydro-thromboxane B2 |
| CN115656400A (en) * | 2022-11-09 | 2023-01-31 | 大连博源医学科技有限公司 | Method for detecting 11-dehydrothromboxane B in urine 2 Liquid chromatography-tandem mass spectrometry method and kit |
| CN115656400B (en) * | 2022-11-09 | 2023-08-18 | 大连博源医学科技有限公司 | Be used for detecting 11-dehydrothromboxane B in urine 2 Liquid chromatography-tandem mass spectrometry method and kit |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kang et al. | Metabolic profiling regarding pathogenesis of idiopathic pulmonary fibrosis | |
| Zhang et al. | Simultaneous determination of tryptophan and kynurenine in plasma samples of children patients with Kawasaki disease by high-performance liquid chromatography with programmed wavelength ultraviolet detection | |
| Zhang et al. | A tandem mass spectrometry assay for the simultaneous determination of acetaminophen, caffeine, phenytoin, ranitidine, and theophylline in small volume pediatric plasma specimens | |
| CN107247093B (en) | The detection method for metanephrine substance of dissociating in urine | |
| Hasselstrøm | Quantification of antidepressants and antipsychotics in human serum by precipitation and ultra high pressure liquid chromatography–tandem mass spectrometry | |
| Chaves et al. | Solid-phase microextraction using poly (pyrrole) film and liquid chromatography with UV detection for analysis of antidepressants in plasma samples | |
| Ansari et al. | A simplified method for busulfan monitoring using dried blood spot in combination with liquid chromatography/tandem mass spectrometry | |
| Goryński et al. | Development of SPME-LC–MS method for screening of eight beta-blockers and bronchodilators in plasma and urine samples | |
| Zhou et al. | Evaluation of the effect of apatinib (YN968D1) on cytochrome P450 enzymes with cocktail probe drugs in rats by UPLC–MS/MS | |
| CN109633063B (en) | Method for detecting concentration of ticagrelor and active metabolite thereof in human plasma | |
| Teixeira et al. | Development of a new HPLC-based method for 3-nitrotyrosine quantification in different biological matrices | |
| CN109030658B (en) | Method for detecting fructo-oligosaccharide and raffinose in infant milk powder | |
| CN109900820A (en) | A kind of method that HPLCMS-MS combination detects Quetiapine in human plasma | |
| CN107941954A (en) | A kind of Monitoring of drug resistance method of aspirin | |
| Kotani et al. | Attomole catechins determination by capillary liquid chromatography with electrochemical detection | |
| Chen et al. | Simultaneous determination of cellular adenosine nucleotides, malondialdehyde, and uric acid using HPLC | |
| JP2013541009A (en) | Sample detection method | |
| Lee et al. | Application of the isoniazid assay in dried blood spots using the ultra-performance liquid chromatography-tandem mass spectrometry | |
| Du et al. | Determination of taurine in human tear fluid by capillary electrophoresis with indirect amperometric detection based on electrogenerated bromine | |
| Dhiman et al. | Analytical reversed‐phase high‐performance liquid chromatography method development for silodosin and solifenacin in bulk and marketed formulation using analytical quality by design approach | |
| Cai et al. | Determination of four pyridine alkaloids from Tripterygium wilfordii Hook. f. in human plasma by high-performance liquid chromatography coupled with mass spectrometry | |
| Won et al. | Analytical Performance Evaluation for Estradiol using Liquid Chromatography–Tandem Mass Spectrometry | |
| CN115656400A (en) | Method for detecting 11-dehydrothromboxane B in urine 2 Liquid chromatography-tandem mass spectrometry method and kit | |
| Sidler‐Moix et al. | A highly sensitive LC–tandem MS assay for the measurement in plasma and in urine of salbutamol administered by nebulization during mechanical ventilation in healthy volunteers | |
| Kim et al. | Simultaneous diagnostic method for phenylketonuria and galactosemia from dried blood spots using high-performance liquid chromatography-pulsed amperometric detection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20190613 Address after: 274000 Room 205, Enlightenment Star, 2059 Zhonghua West Road, Wanfu Office, Heze High-tech Zone, Shandong Province Applicant after: Shandong Boji Medical Technology Co Ltd Address before: 274000 West of Yangying Road, Wanfu Street Office, Mudan District, Heze City, Shandong Province (Nine Industrial Park Area B) Applicant before: Heze Huize clinical research center |
|
| TA01 | Transfer of patent application right | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180420 |
|
| RJ01 | Rejection of invention patent application after publication |